Jeffrey R. Curtis MD, MS, MPH

Curtis2013Associate Professor of Medicine
Director, Arthritis Clinical Intervention Program (ACIP)
Associate Director, Center for Education and Research
on Therapeutics of Musculoskeletal Disorders (CERTS

Address: 
 

Faculty Offices Tower, room 805D
510 20th Street South
Birmingham, AL 35294

Telephone:(205) 975-2176
Email: This email address is being protected from spambots. You need JavaScript enabled to view it.

Education
 

BS (Biology), University of California at San Diego
MD, Oregon Health & Sciences University, Portland, OR
MPH, Oregon Health & Sciences University, Portland, OR
MS (Epidemiology), Harvard School of Public Health
Fellowship, Clinical Immunology and Rheumatology, University of Alabama at Birmingham


Research and Clinical Interests

 
The evaluation of the efficacy, comparative effectiveness, and safety of the medications used to treat rheumatoid arthritis and other forms of inflammatory arthritis are among Dr. Curtis's research interests. He served on the Core Expert Panel for the ACR's 2008 and 2012 Recommendations for the Use of Nonbiologic and Biologic Disease Modifying Antirheumatic Drugs in RA. He currently is the Deputy Director for a collaborative project between the FDA, the Agency for Healthcare Research and Quality (AHRQ), and a number of academic centers studying the safety of biologic agents using multiple, pooled national data sources.

Dr. Curtis also studies risk factors for and outcomes of osteoporosis, particularly among men and non-Caucasians. He was a member of the ACR's task force to update recommendations for the management of glucocorticoid induced osteoporosis (GIOP). He also served on the ASBMR Task Force on Atypical Subtrochanteric and Diaphyseal Fractures.

Dr. Curtis is a member of the American College of Rheumatology (ACR), the International Society for Pharmacoepidemiology (ISPE), and the American Society of Bone and Mineral Research (ASBMR). He has authored more than 150 peer-reviewed articles and book chapters. He is on the editorial board for Pharmacoepidemiology and Drug Safety (PDS) and Arthritis Care and Research (AC&R).
 

Selected Publications


Herrinton LJ, Harrold LR, Liu L, Raebel MA, Taharka A, Winthrop KL, Solomon DH, Curtis JR, Lewis JD, Saag KG. 2013. Association between anti-TNF-α therapy and interstitial lung disease. Pharmacoepidemiol Drug Saf. 2013 Jan 29. PMID: 23359391


Dewitt EM, Li Y, Curtis JR, Glick HA, Greenberg JD, Anstrom KJ, Kremer JM, Reed G, Schulman KA, Reed SD. 2013. Comparative Effectiveness of Nonbiologic versus Biologic Disease-modifying Antirheumatic Drugs for Rheumatoid Arthritis. J Rheumatol. 40(2):127-136. PMID: 23322461


Yazici Y, Curtis JR, Ince A, Baraf HS, Lepley DM, Devenport JN, Kavanaugh A. 2013. Early effects of tocilizumab in the treatment of moderate to severe active rheumatoid arthritis: a 1-week sub-study of a randomised controlled trial (Rapid Onset and Systemic Efficacy [ROSE] Study). Clin Exp Rheumatol. 2013 Jan 10. [Epub ahead of print] PMID: 23305631


Solomon DH, Rassen JA, Kuriya B, Chen L, Harrold LR, Graham DJ, Lewis JD, Lii J, Liu L, Griffin MR, Curtis JR. 2012. Heart failure risk among patients with rheumatoid arthritis starting a TNF antagonist. Ann Rheum Dis. 2012 Nov 15. PMID: 23155221


Herrinton LJ, Liu L, Chen L, Harrold LR, Raebel MA, Curtis JR, Griffin MR, Solomon DH, Saag KG, Lewis JD. 2012. Association between anti-TNF-α therapy and all-cause mortality. Pharmacoepidemiol Drug Saf. 21(12):1311-20. PMID: 23065964


Haynes K, Beukelman T, Curtis JR, Newcomb C, Herrinton LJ, Graham DJ, Solomon DH, Griffin MR, Chen L, Liu L, Saag KG, Lewis JD; SABER Collaboration. 2013. Tumor necrosis factor α inhibitor therapy and cancer risk in chronic immune-mediated diseases. Arthritis Rheum. 65(1):48-58. PMID: 23055441


Curtis JR, Xie F, Chen L, Muntner P, Grijalva CG, Spettell C, Fernandes J, McMahan RM, Baddley JW, Saag KG, Beukelman T, Delzell E. 2012. Use of a disease risk score to compare serious infections associated with anti-tumor necrosis factor therapy among high- versus lower-risk rheumatoid arthritis patients. Arthritis Care Res (Hoboken). 64(10):1480-9. PMID: 22833479


Zhang J, Xie F, Delzell E, Chen L, Winthrop KL, Lewis JD, Saag KG, Baddley JW, Curtis JR. 2012. Association between vaccination for herpes zoster and risk of herpes zoster infection among older patients with selected immune-mediated diseases. JAMA. 308(1):43-9. PMID: 22760290


Curtis JR, van der Helm-van Mil AH, Knevel R, Huizinga TW, Haney DJ, Shen Y, Ramanujan S, Cavet G, Centola M, Hesterberg LK, Chernoff D, Ford K, Shadick NA, Hamburger M, Fleischmann R, Keystone E, Weinblatt ME. 2012. Validation of a novel multibiomarker test to assess rheumatoid arthritis disease activity. Arthritis Care Res (Hoboken). 64(12):1794-803. PMID: 22736476


Curtis JR, Lanas A, John A, Johnson DA, Schulman KL. 2012. Factors associated with gastrointestinal perforation in a cohort of patients with rheumatoid arthritis. Arthritis Care Res (Hoboken). 64(12):1819-28. PMID: 22730417


Curtis JR, Yun H, Lange JL, Matthews R, Sharma P, Saag KG, Delzell E. 2012. Does medication adherence itself confer fracture protection? An investigation of the healthy adherer effect in observational data. Arthritis Care Res (Hoboken). 64(12):1855-63. PMID: 22730364


Curtis JR, Sharma P, Arora T, Bharat A, Barnes I, Morrisey MA, Kilgore M, Saag KG, Wright NC, Yun HG, Delzell E. 2013. Physicians' explanations for apparent gaps in the quality of rheumatology care: Results from the US Medicare Physician Quality Reporting System. Arthritis Care Res (Hoboken). 65(2):235-43. PMID: 22556118

 

SOM Epilogue Menu